UNIVERSITAS
GADJAH MADA
Ekspresi mRNA (Bcl-2, p53, Caspase-9, Caspase-3 dan NGX-6) Sebagai Prediktor Respon Kemoterapi Berbasis Platinum pada Karsinoma Ovarium
ARDHANU KUSUMANTO, Prof. Dr. dr. Heru Pradjatmo, M.Kes. SpOG(K) ; Dr.Med,. dr. Indwiani Astuti, SpFK ; dr. Di
Universitas Gadjah Mada, 2020 | Diunduh dari http://etd.repository.ugm.ac.id/

Daftar Pustaka

Ahmed, A. A., Etemadmoghadam, D., Temple, J., Lynch, A. G., Riad, M., Sharma, R., Stewart, C., Fereday, S., Caldas, C., DeFazio, A., Bowtell, D., & Brenton, J. D. (2010). Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. *Journal of Pathology*, *221*(1), 49–56. https://doi.org/10.1002/path.2696

Anonim. (n.d.-a). *Cell Biology*. https://www.genome.gov/genetics-glossary/

Anonim. (n.d.-b). *tRNA*. http://biology.kenyon.edu/courses/biol114/Chap05/Chapter05.html

Anonim. (2015). *Cancer Facts & Figures 2015*.

Anonim. (2019). *Cancer Stat Facts: Ovarian Cancer*. National Cancer Institute, Surveillance, Epidemiology, and End Results Program. https://seer.cancer.gov/statfacts/html/ovary.html

Arjmand, M., & Avval, F. Z. (2019). *Clinical biomarkers for detection of ovarian cancer*. *2*(1), 3–7.

Berek, J. S., Kehoe, S. T., Kumar, L., & Friedlander, M. (2018). Cancer of the ovary, fallopian tube, and peritoneum. *International Journal of Gynecology and Obstetrics*, *143*, 59–78. https://doi.org/10.1002/ijgo.12614

Bilalović, N., Vranić, S., Hasanagić, S., Basić, H., Tatarević, A., Beslija, S., & Selak, I. (2004). The Bcl-2 protein: a prognostic indicator strongly related to ER and PR in breast cancer. *Bosnian Journal of Basic Medical Sciences / Udruzenje Basicnih Mediciniskih Znanosti = Association of Basic Medical Sciences*, *4*(4), 5–12. https://doi.org/10.17305/bjbms.2004.3352

Borner, C. (2003). The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. *Molecular Immunology*, *39*, 615–647.

Budiana, I. (2013). *ASSOCIATION OF B-CELL LYMPHOMA PROTEIN-2 AND CASPASE-3 EXPRESSION IN OVARIAN CANCER*. *2*, 67–73.

UNIVERSITAS
GADJAH MADA
Ekspresi mRNA (Bcl-2, p53, Caspase-9, Caspase-3 dan NGX-6) Sebagai Prediktor Respon Kemoterapi Berbasis Platinum pada Karsinoma Ovarium
ARDHANU KUSUMANTO, Prof. Dr. dr. Heru Pradjatmo, M.Kes. SpOG(K) ; Dr.Med,. dr. Indwiani Astuti, SpFK ; dr. Di
Universitas Gadjah Mada, 2020 | Diunduh dari http://etd.repository.ugm.ac.id/

Bulun, S. E. (2009). Mechanism of Disease Endometriosis. *The New England Journal of Medicine*, (360), 268–279.

Callahan, M. J., Crum, C. P., Medeiros, F., Kindelberger, D. W., Elvin, J. A., Garber, J. E., Feltmate, C. M., Berkowitz, R. S., & Muto, M. G. (2007). Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. *Journal of Clinical Oncology*, *25*(25), 3985–3990. https://doi.org/10.1200/JCO.2007.12.2622

Carcangiu, M. L., Radice, P., Manoukian, S., Spatti, G., Gobbo, M., Pensotti, V., Crucianelli, R., & Pasini, B. (2004). Atypical Epithelial Proliferation in Fallopian Tubes in Prophylactic Salpingo-oophorectomy Specimens from BRCA1 and BRCA2 Germline Mutation Carriers. *International Journal of Gynecological Pathology*, *23*(1), 35–40. https://doi.org/10.1097/01.pgp.0000101082.35393.84

Chan, J. K., Teoh, D., Hu, J. M., Shin, J. Y., Osann, K., & Kapp, D. S. (2008). Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. *Gynecologic Oncology*, *109*(3), 370–376. https://doi.org/10.1016/j.ygyno.2008.02.006

Chen, W., Zheng, R., Baade, P. D., Zhang, S., Zeng, H., Bray, F., Jemal, A., Yu, X. Q., & He, J. (2016). Cancer statistics in China, 2015. *CA: A Cancer Journal for Clinicians*, *66*(2), 115–132. https://doi.org/10.3322/caac.21338

Cheng, W., Liu, J., Yoshida, H., Rosen, D., & Naora, H. (2005). Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. *Nature Medicine*, *11*(5), 531–537. https://doi.org/10.1038/nm1230

Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994). Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. *Science*, *265*(5170), 346–355. https://doi.org/10.1126/science.8023157

Coleman, M. P., Forman, D., Bryant, H., Butler, J., Rachet, B., Maringe, C., Nur,

UNIVERSITAS
GADJAH MADA
Ekspresi mRNA (Bcl-2, p53, Caspase-9, Caspase-3 dan NGX-6) Sebagai Prediktor Respon Kemoterapi Berbasis Platinum pada Karsinoma Ovarium
ARDHANU KUSUMANTO, Prof. Dr. dr. Heru Pradjatmo, M.Kes. SpOG(K) ; Dr.Med,. dr. Indwiani Astuti, SpFK ; dr. Di
Universitas Gadjah Mada, 2020 | Diunduh dari http://etd.repository.ugm.ac.id/

U., Tracey, E., Coory, M., Hatcher, J., McGahan, C. E., Turner, D., Marrett, L., Gjerstorff, M. L., Johannesen, T. B., Adolfsson, J., Lambe, M., Lawrence, G., Meechan, D., … Richards, M. A. (2011). Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the international cancer benchmarking partnership): An analysis of population-based cancer registry data. *The Lancet*, *377*(9760), 127–138. https://doi.org/10.1016/S0140-6736(10)62231-3

Colgan, T. J., Murphy, J., Cole, D. E. C., Narod, S., & Rosen, B. (2001). Occult carcinoma in prophylactic oophorectomy specimens: Prevalence and association with BRCA germline mutation status. *American Journal of Surgical Pathology*, *25*(10), 1283–1289. https://doi.org/10.1097/00000478-200110000-00009

Cory, S., & Adams, J. M. (2002). The Bcl2 family: regulators of the cellular life-or-death switch. *Cancer*, *2*, 647–656.

Cory, S., Huang, D. C., & Adams, J. M. (2003). The Bcl-2 family: roles in cell survival and oncogenesis. *Oncogene*, *22*, 8590–8607.

Coticchia, C. M., Yang, J., & Moses, M. A. (2008). Ovarian cancer biomarkers: Current options and future promise. *JNCCN Journal of the National Comprehensive Cancer Network*, *6*(8), 795–802. https://doi.org/10.6004/jnccn.2008.0059

Deligdisch, L., Gil, J., Kerner, H., Wu, H. S., Ph, D., Beck, D., & Gershoni-baruch, R. (1999). *Ovarian Dysplasia in Prophylactic Oophorectomy Specimens Cytogenetic and Morphometric Correlations*. 1544–1550.

Deng, F., Xu, X., Lv, M., Ren, B., Wang, Y., Guo, W., Feng, J., & Chen, X. (2017). Age is associated with prognosis in serous ovarian carcinoma. *Journal of Ovarian Research*, *10*(1), 1–9. https://doi.org/10.1186/s13048-017-0331-6

Dole, M. G., Jasty, R., Cooper, M. J., Thompson, C. B., Nuñez, G., & Castle, V. P. (1995). Bcl-xL Is Expressed in Neuroblastoma Cells and Modulates

UNIVERSITAS
GADJAH MADA
Ekspresi mRNA (Bcl-2, p53, Caspase-9, Caspase-3 dan NGX-6) Sebagai Prediktor Respon Kemoterapi Berbasis Platinum pada Karsinoma Ovarium
ARDHANU KUSUMANTO, Prof. Dr. dr. Heru Pradjatmo, M.Kes. SpOG(K) ; Dr.Med,. dr. Indwiani Astuti, SpFK ; dr. Di
Universitas Gadjah Mada, 2020 | Diunduh dari http://etd.repository.ugm.ac.id/

Chemotherapy-induced Apoptosis. *Cancer Research*, *55*(12), 2576–2582.

Dubeau, L. (2008). THE CELL OF ORIGIN OF OVARIAN EPITHELIAL TUMORS. *Lancet Oncology*, *9*(12), 1191–1197.

Fan, T. J., Han, L. H., Cong, R. S., & Liang, J. (2005). Caspase family proteases and apoptosis. *Acta Biochimica et Biophysica Sinica*, *37*(11), 719–727. https://doi.org/10.1111/j.1745-7270.2005.00108.x

Fauvet, R., Dufournet, C., Poncelet, C., Uzan, C., Hugol, D., & Daraï, E. (2005). Expression of pro-apoptotic (p53, p21, bax, bak and fas) and anti-apoptotic (bcl-2 and bcl-x) proteins in serous versus mucinous borderline ovarian tumours. *Journal of Surgical Oncology*, *92*(4), 337–343. https://doi.org/10.1002/jso.20424

Ferlay, J., Soerjomataram, I., Ervik, M., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D., Forman, D., & Bray, F. (2012). *GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012 v1.0 IARC CancerBase No. 11*. https://publications.iarc.fr/Databases/Iarc-Cancerbases/GLOBOCAN-2012-Estimated-Cancer-Incidence-Mortality-And-Prevalence-Worldwide-In-2012-V1.0-2012

Finch, A., Shaw, P., Rosen, B., Murphy, J., Narod, S. A., & Colgan, T. J. (2006). Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. *Gynecologic Oncology*, *100*(1), 58–64. https://doi.org/10.1016/j.ygyno.2005.06.065

Gaitskell, K., Green, J., Pirie, K., Reeves, G., & Beral, V. (2016). *Tubal ligation and ovarian cancer risk in a large cohort : Substantial variation by histological type*. *1084*, 1076–1084. https://doi.org/10.1002/ijc.29856

Ghosh, A., Stewart, D., & Matlashewski, G. (2004). Regulation of Human p53 Activity and Cell Localization by Alternative Splicing. *Molecular and Cellular Biology*, *24*(18), 7987–7997. https://doi.org/10.1128/mcb.24.18.7987-7997.2004

Gilks, C. B. (2010). Molecular Abnormalities in Ovarian Cancer Subtypes Other

UNIVERSITAS
GADJAH MADA
Ekspresi mRNA (Bcl-2, p53, Caspase-9, Caspase-3 dan NGX-6) Sebagai Prediktor Respon Kemoterapi Berbasis Platinum pada Karsinoma Ovarium
ARDHANU KUSUMANTO, Prof. Dr. dr. Heru Pradjatmo, M.Kes. SpOG(K) ; Dr.Med,. dr. Indwiani Astuti, SpFK ; dr. Di
Universitas Gadjah Mada, 2020 | Diunduh dari http://etd.repository.ugm.ac.id/

than High-Grade Serous Carcinoma. *Journal of Oncology*, *2010*, 1–7. https://doi.org/10.1155/2010/740968

Gong, T. T., Wu, Q.-J., Vogtmann, E., Lin, B., & Wang, Y.-L. (2013). Age at menarche and risk of ovarian cancer: a meta-analysis ofepidemiological studies. *Int J Cancer*, *132*(12), 2894–2900.

Griffiths, A. J. F. (2000). tetrad - An Introduction to Genetic Analysis. In *NCBI Bookshelf*. https://www.ncbi.nlm.nih.gov/books/NBK21878/def-item/A5444/

Hainaut, P., & Hollstein, M. (1999). p53 and Human Cancer: The First Ten Thousand Mutations. *Advances in Cancer Research*, *77*(C), 81–86. https://doi.org/10.1016/S0065-230X(08)60785-X

Haldar, S., Chintapalli, J., & Croce, C. M. (1996). Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. *Cancer Research*, *56*(6), 1253–1255.

Haldar, S., Negrini, M., Monne, M., Sabbioni, S., & Croce, C. M. (1994). Down-Regulation of bcl-2 by p53 in Breast Cancer Cells. *Cancer Research*, *54*(8), 2095–2097.

Hanahan, D., & Weinberg, R. A. (2000). The Hallmarks of Cancer. *Cell*, *100*, 57–70.

Harris, C. C. (1996). Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies. *Journal of the National Cancer Institute*, *88*(20), 1442–1455. https://doi.org/10.1093/jnci/88.20.1442

Helm, C. W., & States, J. C. (2009). Enhancing the efficacy of cisplatin in ovarian cancer treatment - Could arsenic have a role. *Journal of Ovarian Research*, *2*(1), 1–7. https://doi.org/10.1186/1757-2215-2-2

Hockenbery, D., Nuñez, G., Milliman, C., Schreiber, R. D., & Korsmeyer, S. (1990). Bcl2 is an inner mitochondrial membrane protein that blocks programmed cell death. *Nature*, *348*, 334–336.

Holschneider, C. H., & Berek, J. S. (2000). *Ovarian Cancer : Epidemiology* ,

UNIVERSITAS
GADJAH MADA
Ekspresi mRNA (Bcl-2, p53, Caspase-9, Caspase-3 dan NGX-6) Sebagai Prediktor Respon Kemoterapi Berbasis Platinum pada Karsinoma Ovarium
ARDHANU KUSUMANTO, Prof. Dr. dr. Heru Pradjatmo, M.Kes. SpOG(K) ; Dr.Med,. dr. Indwiani Astuti, SpFK ; dr. Di
Universitas Gadjah Mada, 2020 | Diunduh dari http://etd.repository.ugm.ac.id/

Biology , and. 3–10.

Hoskins, W. J., McGuire, W. P., Brady, M. F., Homesley, H. D., Creasman, W. T., Berman, M., Ball, H., & Berek, J. S. (1994). The effect of diameter of largest residual disease on survival after primary. *Am.J.Obstet.Gynecol.*, *170*(4), 974–979.

Isobe, M., Emanuel, B. S., Givol, D., Oren, M., & Croce, C. M. (1986). Localization of gene for human p53 tumour antigen to band 17p13. *Nature*, *320*(6057), 84–85. https://doi.org/10.1038/320084a0

Iversen, L., Fielding, S., Lidegaard, Ø., Mørch, L. S., Skovlund, C. W., & Hannaford, P. C. (2018). Association between contemporary hormonal contraception and ovarian cancer in women of reproductive age in Denmark: Prospective, nationwide cohort study. *BMJ (Online)*, *362*, 1–9. https://doi.org/10.1136/bmj.k3609

Jäättelä, M. (1999). Escaping cell death: survival proteins in cancer. *Experimental Cell Research*, *248*, 30–43.

Johnstone, R. W., Ruefli, A. A., & Lowe, S. W. (2002). Apoptosis: A Linkbetween Cancer Geneticsand Chemotherapy. *Cell*, *108*, 153–164.

Jordan, S. J., Webb, P. M., & Green, A. C. (2005). Height, age at menarche, and risk of epithelial ovarian cancer. *Cancer Epidemiology Biomarkers and Prevention*, *14*(8), 2045–2048. https://doi.org/10.1158/1055-9965.EPI-05-0085

Kalloger, S. E., Köbel, M., Leung, S., Mehl, E., Gao, D., Marcon, K. M., Chow, C., Clarke, B. A., Huntsman, D. G., & Gilks, C. B. (2011). Calculator for ovarian carcinoma subtype prediction. *Modern Pathology*, *24*(4), 512–521. https://doi.org/10.1038/modpathol.2010.215

Kern, S. E. (1994). p53: Tumor suppression through control of the cell cycle. *Gastroenterology*, *106*(6), 1708–1711. https://doi.org/10.1016/0016-5085(94)90431-6

Kerr, J., Wyllie, A., & Currie, A. (2005). Apoptosis: A basic biological

UNIVERSITAS
GADJAH MADA
Ekspresi mRNA (Bcl-2, p53, Caspase-9, Caspase-3 dan NGX-6) Sebagai Prediktor Respon Kemoterapi Berbasis Platinum pada Karsinoma Ovarium
ARDHANU KUSUMANTO, Prof. Dr. dr. Heru Pradjatmo, M.Kes. SpOG(K) ; Dr.Med,. dr. Indwiani Astuti, SpFK ; dr. Di
Universitas Gadjah Mada, 2020 | Diunduh dari http://etd.repository.ugm.ac.id/

phenomenon with wide-ranging implications in human disease. *Journal of Internal Medicine*, *258*(6), 479–517. https://doi.org/10.1111/j.1365-2796.2005.01570.x

Kim, A., Ueda, Y., Naka, T., & Enomoto, T. (2012). Therapeutic strategies in epithelial ovarian cancer. *Journal of Experimental & Clinical Cancer Research*, *31*(1), 14. https://doi.org/10.1186/1756-9966-31-14

Kim, D. J., Lee, M. H., Park, T. I., & Bae, H. I. (2006). Expression and mutational analysis of c-kit in ovarian surface epithelial tumors. *Journal of Korean Medical Science*, *21*(1), 81–85. https://doi.org/10.3346/jkms.2006.21.1.81

Kindelberger, D. W., Lee, Y., Miron, A., Hirsch, M. S., Feltmate, C., Medeiros, F., Callahan, M. J., Garner, E. O., Gordon, R. W., Birch, C., Berkowitz, R. S., Muto, M. G., & Crum, C. P. (2007). Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. *American Journal of Surgical Pathology*, *31*(2), 161–169. https://doi.org/10.1097/01.pas.0000213335.40358.47

Kobal, B., Noventa, M., Cvjeticanin, B., Barbic, M., Meglic, L., Herzog, M., Bordi, G., Vitagliano, A., Saccardi, C., & Skof, E. (2018). Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: Comparison of survivals. *Radiology and Oncology*, *52*(3), 307–319. https://doi.org/10.2478/raon-2018-0030

Köbel, M., Huntsman, D., & Gilks, C. B. (2008). Critical molecular abnormalities in high-grade serous carcinoma of the ovary. *Expert Reviews in Molecular Medicine*, *10*(22), 1–14. https://doi.org/10.1017/S146239940800077X

Kurman, R. J., & Shih, I. M. (2016). The dualistic model of ovarian carcinogenesis revisited, revised, and expanded. In *American Journal of Pathology* (Vol. 186, Issue 4, pp. 733–747). American Society for Investigative Pathology. https://doi.org/10.1016/j.ajpath.2015.11.011

Landis, S. H. (1999). *Cancer Statistics , 1999.*

Lauchlan, S. C. (1994). The secondary Mullerian system revisited.pdf.

UNIVERSITAS
GADJAH MADA
Ekspresi mRNA (Bcl-2, p53, Caspase-9, Caspase-3 dan NGX-6) Sebagai Prediktor Respon Kemoterapi Berbasis Platinum pada Karsinoma Ovarium
ARDHANU KUSUMANTO, Prof. Dr. dr. Heru Pradjatmo, M.Kes. SpOG(K) ; Dr.Med,. dr. Indwiani Astuti, SpFK ; dr. Di
Universitas Gadjah Mada, 2020 | Diunduh dari http://etd.repository.ugm.ac.id/

International Journal of Gynecological Pathology, *13*, 73–79.

Leek, R. D., Kaklamanis, L., Pezzella, F., & Gatter, K. C. (1994). Bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. *British Journal of Cancer*, *69*(1), 135–139. https://doi.org/10.1038/bjc.1994.22

Levine, A. J. (1997). p53, the Cellular Gatekeeper for Growth and Division. *Cell*, *88*, 323–331.

Levine, B., Sinha, S., & Kroemer, G. (2008). BCL-2 family members. *Autophagy*, *4*(5), 600–606. https://doi.org/10.1016/j.bbi.2008.05.010

Liu, M., Peng, Y., Wang, X., Guo, Q., Shen, S., & Li, G. (2010). NGX6 gene mediated by promoter methylation as a potential molecular marker in colorectal cancer. *BMC Cancer*, *10*. https://doi.org/10.1186/1471-2407-10-160

Loeb, K. R., & Loeb, L. A. (2000). Significance of multiple mutations in cancer. *Carcinogenesis*, *21*(3), 379–385.

Lohmann, C. M., League, A. A., Clark, W. S., Lawson, D., DeRose, P. B., & Cohen, C. (2000). Bcl-2: Bax and bcl-2: Bcl-x ratios by image cytometric quantitation of immunohistochemical expression in ovarian carcinoma: Correlation with prognosis. *Communications in Clinical Cytometry*, *42*(1), 61–66. https://doi.org/10.1002/(SICI)1097-0320(20000215)42:1<61::AID-CYTO9>3.0.CO;2-5

Lu, Q. L., Abel, P., Foster, C. S., & Lalani, E. N. (1996). bcl-2: Role in epithelial differentiation and oncogenesis. *Human Pathology*, *27*(2), 102–110. https://doi.org/10.1016/S0046-8177(96)90362-7

Makar, A. P., Trope, C. G., Tummers, P., Denys, H., & Vandecasteele, K. (2016). Advanced Ovarian Cancer: Primary or Interval Debulking? FiveCategories of Patients in View of the Results of Randomized Trials andTumor Biology: Primary Debulking Surgery and Interval DebulkingSurgery for Advanced Ovarian Cancer. *The Oncologist*, *21*, 745–754.

UNIVERSITAS
GADJAH MADA
Ekspresi mRNA (Bcl-2, p53, Caspase-9, Caspase-3 dan NGX-6) Sebagai Prediktor Respon Kemoterapi Berbasis Platinum pada Karsinoma Ovarium
ARDHANU KUSUMANTO, Prof. Dr. dr. Heru Pradjatmo, M.Kes. SpOG(K) ; Dr.Med,. dr. Indwiani Astuti, SpFK ; dr. Di
Universitas Gadjah Mada, 2020 | Diunduh dari http://etd.repository.ugm.ac.id/

Mano, Y., Kikuchi, Y., Yamamoto, K., Kita, T., Hirata, J., Tode, T., Ishii, K., & Nagata, I. (1999). Bcl-2 as a predictor of chemosensitivity and prognosis in primary epithelial ovarian cancer. *European Journal of Cancer*, *35*(8), 1214–1219. https://doi.org/10.1016/S0959-8049(99)00124-0

Mantovani, F., Collavin, L., & Del Sal, G. (2019). Mutant p53 as a guardian of the cancer cell. *Cell Death and Differentiation*, *26*(2), 199–212. https://doi.org/10.1038/s41418-018-0246-9

Martin, D. C. (1997). Cancer and Endometriosis: Do We Need to Be Concerned? *Seminars in Reproductive Endocrinology*, *15*(3), 319–324.

Marx, D., & Meden, H. (2001). Differential Expression of Apoptosis-AssociatedGenesbaxandbcl-2 in Ovarian Cancer. In *Ovarian Cancer* (pp. 687–691).

McCluggage, W. G. (2011). Morphological subtypes of ovarian carcinoma : a review with emphasis on new developments and pathogenesis. *Pathology*, *43*(August), 420–432. https://doi.org/10.1097/PAT.0b013e328348a6e7

McGuire, V., Hartge, P., Liao, L. M., Sinha, R., Bernstein, L., Canchola, A. J., Anderson, G. L., Stefanick, M. L., & Whittemore, A. S. (2016). Parity and oral contraceptive use in relation to ovarian cancer risk in older women. *Cancer Epidemiology Biomarkers and Prevention*, *25*(7), 1059–1063. https://doi.org/10.1158/1055-9965.EPI-16-0011

McGuire, W. P., & Markman, M. (2003). Primary ovarian cancer chemotherapy: Current standards of care. In *British Journal of Cancer* (Vol. 89, Issue SUPPL. 3, pp. 3–8). https://doi.org/10.1038/sj.bjc.6601494

McGuire, William Patrick. (2009). Maintenance therapy for ovarian cancer: Of Helsinki and Hippocrates. *Journal of Clinical Oncology*, *27*(28), 4633–4634. https://doi.org/10.1200/JCO.2009.23.6653

McIlwain, D. R., Berger, T., & Mak, T. W. (2013). Caspase functions in cell death and disease. *Cold Spring Harbor Perspectives in Biology*, *5*(4), 1–28. https://doi.org/10.1101/cshperspect.a008656

UNIVERSITAS
GADJAH MADA
Ekspresi mRNA (Bcl-2, p53, Caspase-9, Caspase-3 dan NGX-6) Sebagai Prediktor Respon Kemoterapi Berbasis Platinum pada Karsinoma Ovarium
ARDHANU KUSUMANTO, Prof. Dr. dr. Heru Pradjatmo, M.Kes. SpOG(K) ; Dr.Med,. dr. Indwiani Astuti, SpFK ; dr. Di
Universitas Gadjah Mada, 2020 | Diunduh dari http://etd.repository.ugm.ac.id/

Medeiros, F., Muto, M. G., Lee, Y., Elvin, J. A., Callahan, M. J., Feltmate, C., Garber, J. E., Cramer, D. W., & Crum, C. P. (2006). *The Tubal Fimbria Is a Preferred Site for Early Adenocarcinoma in Women With Familial Ovarian Cancer Syndrome*. *30*(2), 230–236.

Minn, A. J., Vélez, P., Schendel, S. L., Liang, H., Muchmore, S. W., Fesik, S. W., Fill, M., & Thompson, C. B. (1997). Bcl-x(L) forms an ion channel in synthetic lipid membranes. *Nature*, *385*, 353–357.

Muchmore, S. W., Sattler, M., Liang, H., Meadows, R. P., Harlabn, J. E., Yoon, H. S., Nettesheim, D., Chang, B. S., Thompson, C. B., Wong, S.-L., Ng, S.-C., & Fesik, S. W. (1996). X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. *Nature*, *381*, 335–341.

Nguyen, H. N., Averette, H. E., Hoskins, W., Sevin, B. □U, Penalver, M., & Steren, A. (1993). National survey of ovarian carcinoma VI: Critical assessment of Current International Federation of Gynecology and Obstetrics Staging System. *Cancer*, *72*(10), 3007–3011. https://doi.org/10.1002/1097-0142(19931115)72:10<3007::AID-CNCR2820721024>3.0.CO;2-N

Ogston, S. A., Lemeshow, S., Hosmer, D. W., Klar, J., & Lwanga, S. K. (1991). Adequacy of Sample Size in Health Studies. In *Biometrics* (Vol. 47, Issue 1). https://doi.org/10.2307/2532527

Omura, G., Blessing, J. A., Ehrlich, C. E., Miller, A., Yordan, E., Creasman, W. T., & Homesley, H. D. (1986). A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A gynecologic oncology group study. *Cancer*, *57*(9), 1725–1730. https://doi.org/10.1002/1097-0142(19860501)57:9<1725::AID-CNCR2820570903>3.0.CO;2-J

Paley, P. J., Swisher, E. M., Garcia, R. L., Agoff, S. N., Greer, B. E., Peters, K. L., & Goff, B. A. (2001). Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: A case for recommending hysterectomy at surgical prophylaxis. *Gynecologic Oncology*,

UNIVERSITAS
GADJAH MADA
Ekspresi mRNA (Bcl-2, p53, Caspase-9, Caspase-3 dan NGX-6) Sebagai Prediktor Respon Kemoterapi Berbasis Platinum pada Karsinoma Ovarium
ARDHANU KUSUMANTO, Prof. Dr. dr. Heru Pradjatmo, M.Kes. SpOG(K) ; Dr.Med,. dr. Indwiani Astuti, SpFK ; dr. Di
Universitas Gadjah Mada, 2020 | Diunduh dari http://etd.repository.ugm.ac.id/

80(2), 176–180. https://doi.org/10.1006/gyno.2000.6071

Petros, A., Medek, A., Nettesheim, D., Kim, D., Yoon, H., Swift, K., Matayoshi, E., Oltersdorf, T., & Fesik, S. (2001). *1G5M Human BCL-2, ISOFORM 1*. RSCB Protein Data Bank. https://doi.org/10.2210/pdb1G5M/pdb

Piek, J. M. J., Bulten, J., van Diest, P. J., Massuger, L. F., Zweemer, R. P., & Verheijen, R. H. M. (2003). DYSPLASTIC CHANGES IN PROPHYLACTICALLY REMOVED FALLOPIAN TUBES OF WOMEN PREDISPOSED TO DEVELOP OVARIAN/FALLOPIAN TUBE CANCER. *International Journal of Gynecologic Cancer*, *13*(Suppl 1), 89.3-89. https://doi.org/10.1136/ijgc-00009577-200303001-00327

Pignata, S., Scambia, G., Ferrandina, G., Savarese, A., Sorio, R., Breda, E., Gebbia, V., Musso, P., Frigerio, L., Del Medico, P., Lombardi, A. V., Febbraro, A., Scollo, P., Ferro, A., Tamberi, S., Brandes, A., Ravaioli, A., Valerio, M. R., Aitini, E., … Perrone, F. (2011). Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: The MITO-2 randomized phase III trial. *Journal of Clinical Oncology*, *29*(27), 3628–3635. https://doi.org/10.1200/JCO.2010.33.8566

Pistritto, G., Trisciuoglio, D., Ceci, C., Alessia Garufi, & D'Orazi, G. (2016). Apoptosis as anticancer mechanism: Function and dysfunction of its modulators and targeted therapeutic strategies. *Aging*, *8*(4), 603–619. https://doi.org/10.18632/aging.100934

Pomel, C., Jeyarajah, A., Oram, D., Shepherd, J., Milliken, D., Dauplat, J., & Reynolds, K. (2007). Cytoreductive surgery in ovarian cancer. *Cancer Imaging*, *7*(1), 210–215. https://doi.org/10.1102/1470-7330.2007.0030

Raja, F. A., Chopra, N., & Ledermann, J. A. (2012). symposium article Optimal fi rst-line treatment in ovarian cancer. *Educational Book of the 37th ESMO Congress, Vienna, Austria, 28 September – 2 October 2012*, *23*(Supplement 10), x118–x127. https://doi.org/10.1093/annonc/mds315

UNIVERSITAS
GADJAH MADA
Ekspresi mRNA (Bcl-2, p53, Caspase-9, Caspase-3 dan NGX-6) Sebagai Prediktor Respon Kemoterapi Berbasis Platinum pada Karsinoma Ovarium
ARDHANU KUSUMANTO, Prof. Dr. dr. Heru Pradjatmo, M.Kes. SpOG(K) ; Dr.Med,. dr. Indwiani Astuti, SpFK ; dr. Di
Universitas Gadjah Mada, 2020 | Diunduh dari http://etd.repository.ugm.ac.id/

Reece, J. B., Urry, L. A., Cain, M. L., Campbell, N. A., Minorsky, P. V, Jackson, R. B., & Wasserman, S. A. (2012). *Biology* (10th ed.). Pearson Publishing.

Reed, J. C. (1995). Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. *Oncology*, *7*, 541–546.

Reed, J. C. (1997). Double identity for proteins of the Bcl-2 family. *Nature*, *387*(6635), 773–776. https://doi.org/10.1038/42867

Reid, B. M., Permuth, J. B., & Sellers, T. A. (2017). Epidemiology of ovarian cancer: a review. *Cancer Biology and Medicine*, *14*(1), 9–32. https://doi.org/10.20892/j.issn.2095-3941.2016.0084

Schendel, S. L., Xie, Z., Montal, M. O., Matsuyama, S., Montal, M., & Reed, J. C. (1997). Channel formation by antiapoptotic protein Bcl-2. *Proceedings of the National Academy of Sciences of the United States of America*, *94*(10), 5113–5118. https://doi.org/10.1073/pnas.94.10.5113

Schuyer, M., Van der Burg, M. E. L., Henzen-Logmans, S. C., Fieret, J. H., Klijn, J. G. M., Look, M. P., Foekens, J. A., Stoter, G., & Berns, E. M. J. J. (2001). Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: A multifactorial analysis of TP53, p21, BAX and BCL-2. *British Journal of Cancer*, *85*(9), 1359–1367. https://doi.org/10.1054/bjoc.2001.2101

Seidman, Jeffery D, Cho, K. R., Ronnet, B. M., & Kurman, R. J. (2002). Surface Epithelial Tumors of the Ovary. In R. J. Kurman, L. H. Ellenson, & B. M. Ronnett (Eds.), *Blaustein's Pathology of the Female Genital Tract* (6th ed., pp. 679–784). Springer.

Seidman, Jeffrey D., Horkayne-Szakaly, I., Haiba, M., Boice, C. R., Kurman, R. J., & Ronnett, B. M. (2004). The Histologic Type and Stage Distribution of Ovarian Carcinomas of Surface Epithelial Origin. *International Journal of Gynecological Pathology*, *23*(1), 41–44. https://doi.org/10.1097/01.pgp.0000101080.35393.16

Sekulic, A., Haluska, P., Miller, A. J., De Lamo, J. G., Ejadi, S., Pulido, J. S.,

UNIVERSITAS
GADJAH MADA
Ekspresi mRNA (Bcl-2, p53, Caspase-9, Caspase-3 dan NGX-6) Sebagai Prediktor Respon Kemoterapi Berbasis Platinum pada Karsinoma Ovarium
ARDHANU KUSUMANTO, Prof. Dr. dr. Heru Pradjatmo, M.Kes. SpOG(K) ; Dr.Med,. dr. Indwiani Astuti, SpFK ; dr. Di
Universitas Gadjah Mada, 2020 | Diunduh dari http://etd.repository.ugm.ac.id/

Salomao, D. R., Thorland, E. C., Vile, R. G., Swanson, D. L., Pockaj, B. A., Laman, S. D., Pittelkow, M. R., & Markovic, S. N. (2008). Malignant melanoma in the 21st century: The emerging molecular landscape. *Mayo Clinic Proceedings*, *83*(7), 825–846. https://doi.org/10.4065/83.7.825

Shaw, P. A., Rouzbahman, M., Pizer, E. S., Pintilie, M., & Begley, H. (2009). Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers. *Modern Pathology*, *22*(9), 1133–1138. https://doi.org/10.1038/modpathol.2009.89

Sherman, M. E., Lee, J. S., Burks, R. T., Struewing, J. P., Kurman, R. J., & Hartge, P. (1999). Histopathologic features of ovaries at increased risk for carcinoma. A case-control analysis. *International Journal of Gynecological Pathology*, *18*, 151–157.

Shih, I. M., & Kurman, R. J. (2004). Ovarian Tumorigenesis: A Proposed Model Based on Morphological and Molecular Genetic Analysis. *American Journal of Pathology*, *164*(5), 1511–1518. https://doi.org/10.1016/S0002-9440(10)63708-X

Shimizu, Y., Kamoi, S., Amada, S., Hasumi, K., Akiyama, F., & Silverberg, S. G. (1998). Toward the development of a universal grading system for ovarian epithelial carcinoma I. Prognostic significance of histopathologic features-problems involved in the architectural grading system. *Gynecologic Oncology*, *70*(1), 2–12. https://doi.org/10.1006/gyno.1998.5051

Silvestrini, R., Veneroni, S., Daidone, M. G., Benini, E., Boracchi, P., Mezzetti, M., Di Fronzo, G., Rilke, F., & Veronesi, U. (1994). The Bcl-2 Protein: a Prognostic IndicatorStrongly Related to p53 Protein in LymphNode-Negative Breast Cancer Patients. *Journal of the National Cancer Institute*, *86*(7), 499–504.

Singh, N., Gilks, C. B., Wilkinson, N., & McCluggage, W. G. (2015). The secondary Müllerian system, field effect, BRCA, and tubal fimbria: our evolving understanding of the origin of tubo-ovarian high-grade serous

UNIVERSITAS
GADJAH MADA
Ekspresi mRNA (Bcl-2, p53, Caspase-9, Caspase-3 dan NGX-6) Sebagai Prediktor Respon Kemoterapi Berbasis Platinum pada Karsinoma Ovarium
ARDHANU KUSUMANTO, Prof. Dr. dr. Heru Pradjatmo, M.Kes. SpOG(K) ; Dr.Med,. dr. Indwiani Astuti, SpFK ; dr. Di
Universitas Gadjah Mada, 2020 | Diunduh dari http://etd.repository.ugm.ac.id/

carcinoma and why assignment of primary site matters. In *Pathology* (Vol. 47, Issue 5, pp. 423–431). https://doi.org/10.1097/PAT.0000000000000291

Skírnisdóttir, I., & Seidal, T. (2012). The apoptosis regulators p53, bax and PUMA: Relationship and impact on outcome in early stage (FIGO I-II) ovarian carcinoma after post-surgical taxane-based treatment. *Oncology Reports*, *27*(3), 741–747. https://doi.org/10.3892/or.2011.1578

Skirnisdóttir, I., Sorbe, B., & Seidal, T. (2001). P53, bcl-2, and bax: Their relationship and effect on prognosis in early stage epithelial ovarian carcinoma. *International Journal of Gynecological Cancer*, *11*(2), 147–158. https://doi.org/10.1046/j.1525-1438.2001.01003.x

Solomon, E., Martin, C., Martin, D. W., & Berg, L. R. (2008). *Biology* (8th ed.). Thomson Brooks/Cole.

Tapia, G., & Diaz-Padilla, I. (2013). Molecular Mechanisms of Platinum Resistance in Ovarian Cancer. In *Ovarian Cancer - A Clinical and Translational Update* (pp. 2015–2223). https://www.intechopen.com/books/ovarian-cancer-a-clinical-and-translational-update/molecular-mechanisms-of-platinum-resistance-in-ovarian-cancer

Tas, F., Duranyildiz, D., Oguz, H., Camlica, H., Yasasever, V., & Topuz, E. (2006). The value of serum bcl-2 levels in advanced epithelial ovarian cancer. *Medical Oncology*, *23*(2), 213–217. https://doi.org/10.1385/MO:23:2:213

Tavassoli, F., & Devilee, P. (2003). *Pathology and Genetics: Tumours of the Breast and Female Genital Organs*. IARC Press.

Tchelebi, L., Ashamalla, H., & Graves, P. R. (2014). Mutant p53 and MDM2 in Cancer. *Sub-Cellular Biochemistry*, *85*, 133–159. https://doi.org/10.1007/978-94-017-9211-0

Ueland, F. (2017). A Perspective on Ovarian Cancer Biomarkers: Past, Present and Yet-To-Come. *Diagnostics*, *7*(1), 14.

UNIVERSITAS
GADJAH MADA
Ekspresi mRNA (Bcl-2, p53, Caspase-9, Caspase-3 dan NGX-6) Sebagai Prediktor Respon Kemoterapi Berbasis Platinum pada Karsinoma Ovarium
ARDHANU KUSUMANTO, Prof. Dr. dr. Heru Pradjatmo, M.Kes. SpOG(K) ; Dr.Med,. dr. Indwiani Astuti, SpFK ; dr. Di
Universitas Gadjah Mada, 2020 | Diunduh dari http://etd.repository.ugm.ac.id/

https://doi.org/10.3390/diagnostics7010014

Vaux, D. L., Cory, S., & Adams, J. M. (1988). Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. In *Nature* (Vol. 335, Issue 6189, pp. 440–442). https://doi.org/10.1038/335440a0

Veras, E., Mao, T. L., Ayhan, A., Ueda, S., Lai, H., Hayran, M., Shih, I. M., & Kurman, R. J. (2009). Cystic and adenofibromatous clear cell carcinomas of the ovary: Distinctive tumors that differ in their pathogenesis and behavior: A clinicopathologic analysis of 122 cases. *American Journal of Surgical Pathology*, *33*(6), 844–853. https://doi.org/10.1097/PAS.0b013e31819c4271

Verma, P., Chierzi, S., Codd, A. M., Campbell, D. S., Meyer, R. L., Holt, C. E., & Fawcett, J. W. (2005). Axonal protein synthesis and degradation are necessary for efficient growth cone regeneration. *Journal of Neuroscience*, *25*(2), 331–342. https://doi.org/10.1523/JNEUROSCI.3073-04.2005

Vogelstein, B., Lane, D., & Levine, A. J. (2000). Surfing the p53 network. *Nature*, *408*, 307–310.

Wong, K. K., Izaguirre, D. I., Kwan, S. Y., King, E. R., Deavers, M. T., Sood, A. K., Mok, S. C., & Gershenson, D. M. (2013). Poor survival with wild-type TP53 ovarian cancer? *Gynecologic Oncology*, *130*(3), 565–569. https://doi.org/10.1016/j.ygyno.2013.06.016

Wong, R. S. Y. (2011). Apoptosis in cancer: From pathogenesis to treatment. *Journal of Experimental and Clinical Cancer Research*, *30*(1), 87. https://doi.org/10.1186/1756-9966-30-87

Wood, M. E., Garber, J. E., Isaacs, C., Masood, S., Bedrosian, I., Tung, N., Chun, J., Schnabel, F. R., & Arun, B. K. (2019). Genetic testing for hereditary breast and ovarian cancer and the USPSTF recommendations. *Breast Journal*, *25*(4), 575–577. https://doi.org/10.1111/tbj.13292

Woodward, E. R., Sleightholme, H. V., Considine, A. M., Williamson, S., McHugo, J. M., & Cruger, D. G. (2007). Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population

UNIVERSITAS
GADJAH MADA
Ekspresi mRNA (Bcl-2, p53, Caspase-9, Caspase-3 dan NGX-6) Sebagai Prediktor Respon Kemoterapi Berbasis Platinum pada Karsinoma Ovarium
ARDHANU KUSUMANTO, Prof. Dr. dr. Heru Pradjatmo, M.Kes. SpOG(K) ; Dr.Med,. dr. Indwiani Astuti, SpFK ; dr. Di
Universitas Gadjah Mada, 2020 | Diunduh dari http://etd.repository.ugm.ac.id/

risk women is ineffective. *BJOG: An International Journal of Obstetrics and Gynaecology*, *114*(12), 1500–1509. https://doi.org/10.1111/j.1471-0528.2007.01499.x

Xiao, J., Zhou, Y., & Zhu, W. (2015). Association of ultrasonographic features with NGX6 expression and prognosis in invasive ductal breast carcinoma. *International Journal of Clinical and Experimental Pathology*, *8*(6), 6458–6465.

Xu, X., Deng, F., Lv, M., Ren, B., Guo, W., & Chen, X. (2016). Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer. *Journal of Ovarian Research*, *9*(1), 1–8. https://doi.org/10.1186/s13048-016-0294-z

Yoshikawa, K., Fukuda, T., Uemura, R., Matsubara, H., Wada, T., Kawanishi, M., Tasaka, R., Kasai, M., Hashiguchi, Y., Ichimura, T., Yasui, T., & Sumi, T. (2018). Age□related differences in prognosis and prognostic factors among patients with epithelial ovarian cancer. *Molecular and Clinical Oncology*. https://doi.org/10.3892/mco.2018.1668

Zhao, W. J., & Wang, K. (2013). NGX6 expression improves the sensitivity of tamoxifen-resistant MCF-7 cells through modulation of the Smad signaling pathway. *International Journal of Oncology*, *42*(6), 2060–2068. https://doi.org/10.3892/ijo.2013.1886